Recently, in addition to ICI monotherapy, combination immunotherapy (ICIs and cytotoxic anticancer agents; anti‐PD‐1 and anticytotoxic‐T‐lymphocyte‐associated protein 4 (CTLA‐4) antibodies; and anti‐PD‐1 antibody, anti‐CTLA‐4 antibody, and cytotoxic anticancer agents) is recommended for previously untreated NSCLC, which has further improved the prognosis of advanced NSCLC.1, 2, 3, 4, 5, 6, 7. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.